Transparency in Nigeria's public pharmaceutical sector: Perceptions from policy makers

Globalization and Health

Volumn 5, Issue , 2009, Pages

  Garuba, Habibat A ^a   Kohler, Jillian C ^a   Huisman, Anna M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CORRUPTION; DEVELOPING WORLD; ECONOMIC ACTIVITY; GOVERNANCE APPROACH; HEALTH CARE; NUMERICAL MODEL; PHARMACEUTICAL INDUSTRY; POLICY MAKING; PUBLIC HEALTH; PUBLIC SECTOR; QUALITATIVE ANALYSIS; REGULATORY FRAMEWORK; STAKEHOLDER; TRAFFICKING; WORLD HEALTH ORGANIZATION;

ANTISOCIAL BEHAVIOR; ARTICLE; FOOD AND DRUG ADMINISTRATION; FOOD CONTROL; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH SERVICE; HUMAN; NIGERIA; PHARMACEUTICAL CARE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; REGISTRATION; SEMI STRUCTURED INTERVIEW; WORLD HEALTH ORGANIZATION;

NIGERIA;

EID: 80054967286     PISSN: None     EISSN: 17448603     Source Type: Journal    
DOI: 10.1186/1744-8603-5-14     Document Type: Article

References (33)

1. Baghdadi-Sabeti G, Wondemagegnehu E. Measuring Transparency in Medicines Registration, Selection and Procurement, Four Country Assessment Studies 2006, Geneva: World Health Organization Press.
2. Cohen JC, Mrazek MF, Hawkins L. Corruption and Pharmaceuticals, Strengthening Good Governance to Improve Access. The Many Faces of Corruption Tracking Vulnerabilities at the Sector Level 2007, Washington: The WorldBank, Campos JE, Pradhan S.
3. Hanif M, Mobarak MR, Ronan A, Rahman D, Donovan JJ, Bennish ML. Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. Br Med J 1995, 311(6997):88-91.
4. Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, Bruneton C, Phanouvong S, Millet P, Whitty CJM, Talisuna AO, Proux S, Christophe E, Malenga G, Singhasivanon P, Bojang K, Kaur H, Palmer K, Day NPJ, Greenwood BM, Nosten F, White NJ. Manslaughter by fake artesunate in Asia - will Africa be next?. PLoS Med 2006, 3(6):e197. 1475657, 16752952, 10.1371/journal.pmed.0030197.
5. O'Brien KL, Selaniko JD, Hecdivert C, Placide MF, Louis M, Barr DBC, James Hospedales CJ, Lewis MJ, Schwartz B, Philen RM, St Victor S, Espindola J, Needham LL, Denerville K. Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning. JAMA 1998, 279(15):1175-80. 10.1001/jama.279.15.1175, 9555756.
6. World Health Organization Department of Essential Drugs and Other Medicines Counterfeit drugs: guidelines for the development of measures to combat counterfeit drugs 1999, Geneva: World Health Organization Press, World Health Organization Department of Essential Drugs and Other Medicines.
7. Cohen JC. Pharmaceuticals and corruption: a risk assessment. Global Corruption Report 2006 2006, 77-84. London: Transparency International.
8. Transparency International What is Corruption?. Transparency International., http://www.transparency.org/about_us
9. Erhun WO, Babalola OO, Erhun MO. Drug regulation and control in Nigeria: the challenge of counterfeit drugs. J Health Popul Dev Ctries 2001, 4(2):23-4.
10. The National Agency for Food and Drug Administration and Control (NAFDAC) Fake Drugs and Substandard Regulated Products. The National Agency for Food and Drug Administration and Control (NAFDAC)., http://www.nafdacnigeria.org/identified.html
11. The National Agency for Food and Drug Administration and Control (NAFDAC) Journey So Far. Cited February 15, 2009., The National Agency for Food and Drug Administration and Control (NAFDAC)., http://www.nafdacnigeria.org/journey.html
12. The National Agency for Food and Drug Administration and Control (NAFDAC) NAFDAC destroys N10B fake drugs in 4 years. NAFDAC News 2006, 1(10):4. The National Agency for Food and Drug Administration and Control (NAFDAC).
13. The National Agency for Food and Drug Administration and Control (NAFDAC) Gains. Cited November 2, 2007., The National Agency for Food and Drug Administration and Control (NAFDAC)., http://www.nafdacnigeria.org/gains.html
14. World Health Organization Fake drugs: A scourge of the system. WHO Drug Inf 1995, 9:127-129. World Health Organization.
15. Akunyil D. Counterfeit and Substandard Drugs, Nigeria's Experience: Implications, Challenges, Actions and Recommendations. Talk for NAFDAC at a Meeting for Key Interest Groups on Health 2005, The World Bank.
16. Shakoor O, Taylor R, Behrens R. Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health 1997, 2(9):839-45. 10.1046/j.1365-3156.1997.d01-403.x, 9315042.
17. Akunyili D. The fight against counterfeit drugs in Nigeria. Pharmaceuticals and corruption: a risk assessment. Global Corruption Report 2006 2006, 96-99. London: Transparency International.
18. Nnani I. Baseline study to ascertain the level and quality of unregistered drugs on the market. 2001, National Food and Drug Administration and Control (NAFDAC).
19. Morris J, Stevens P. Counterfeit medicines in less developed countries: problems and solutions 2006, London: International Policy Network: International Policy Press.
20. National Agency for Food and Drug Administration and Control (NAFDAC) Directorates. Cited February 18, 2009., National Agency for Food and Drug Administration and Control (NAFDAC)., http://www.nafdac.gov.ng/index.php?option=com_content&view=article&id=51&Itemid=54
21. World Health Organization Department of Medicines Policy and Standards (PSM) and Department of Ethics, Trade, Human Rights, and Health Law (ETH) of the World Trade Organization Measuring transparency to improve good governance in the public pharmaceutical sector: assessment instrument. Working document for field testing and revision (Rev I) 2007, Geneva: World Health Organization Press, World Health Organization Department of Medicines Policy and Standards (PSM) and Department of Ethics, Trade, Human Rights, and Health Law (ETH) of the World Trade Organization.
22. Cohen JC, Cercone J, Macaya R. Improving transparency in the pharmaceutical system: the case of Costa Rica 2002, Washington: The World Bank.
23. National Agency for Food and Drug Administration and Control (NAFDAC) Registration and Regulatory Affairs Directorate FAQ. Cited February 18, 2009., National Agency for Food and Drug Administration and Control (NAFDAC)., http://www.nafdac.gov.ng/index.php?option=com_content&view=article&id=84&Itemid=117
24. Raufu AI. Nigeria leads fight against "killer" counterfeit drugs. Bulletin of the World Health Organization 2006, 84(9):685-764.
25. Oparah AC, Eferakeya AE. Attitudes of Nigerian Pharmacists towards Pharmaceutical Care. Pharm World Sci 2005, 27:208-214. 10.1007/s11096-004-2268-2, 16096889.
26. The National Agency for Food and Drug Administration and Control (NAFDAC) NAFDAC smashes water for injection syndicate. NAFDAC News 2006, 1(10):47. The National Agency for Food and Drug Administration and Control (NAFDAC).
27. Cohen JC, Montoya JC. Using technology to fight corruption in pharmaceutical purchasing: lessons learned from the Chilean experience. 2001, The World Bank.
28. McMahon G. Regulatory capture: causes and effects. International Institute for Public Ethics (IIPE) Biennial Conference: 4-7 October 2002: Brisbane, Australia
29. Nuhu SZ. The Future of Pharmacy in Nigeria: The Challenges Ahead. Nigerian Journal of Pharmacy 2003, 34:11-14.
30. Alo A. Pharmacy in Nigeria. Am J of Health Syst Pharm 2006, 63:670-673.
31. Erhun WO, Demehin AI, Erhun MO. Impact of Global Pharmaceutical Mergers and Acquisitions on the Nigerian Pharmaceutical Industry. Journal of Medical Marketing 2005, 5(4):370-382.
32. Canadian Agency for Drugs and Technologies in Health Conflict of Interest Guidelines for the Common Drug Review. Cited July 15, 2009., Canadian Agency for Drugs and Technologies in Health., http://www.cadth.ca/media/cdr/committees/cedac/cdr_conflict_of_interest_guidelines_e.pdf
33. World Health Organization Counterfeit Medicines. Cited December 5, 2007., World Health Organization., http://www.who.int/medicines/services/counterfeit/impact/ImpactF_S/en/index.html